By ZH Sailing | China Global Expansion
March 2026
China’s pharmaceutical sector is undergoing a quiet but profound shift—from a fast-growing market for global drugmakers into an increasingly important source of innovation for the global healthcare industry.
For multinational companies, this transformation is prompting a strategic reassessment: China is no longer just a destination for sales, but a partner in developing and scaling new therapies worldwide.
From Market to Innovation Engine
The scale of China’s rise in pharmaceutical innovation is becoming difficult to ignore.
Recent data suggest that the country now contributes roughly 30 percent of global healthcare innovation, reflecting rapid advances in biotechnology, clinical research, and regulatory efficiency.
In 2025 alone:
-
76 innovative drugs were approved for market entry
-
Outbound licensing deals exceeded $130 billion
-
More than 150 license-out agreements were completed
These figures point to a structural shift: China is moving up the value chain from drug manufacturing and generics toward original innovation and global commercialization.
Multinationals Reposition as Partners
This shift is reshaping how global pharmaceutical companies engage with China.
Merck, one of Europe’s leading healthcare and life sciences groups, is among those adapting its strategy. Rather than focusing solely on selling into China, the company is seeking to position itself as a “preferred partner” for Chinese innovators.
The goal is to combine:
-
China’s growing R&D capabilities
-
With global expertise in commercialization, regulation, and market access
This partnership model reflects a broader trend across the industry, as multinationals increasingly act as bridges between Chinese innovation and global markets.
Turning Innovation into Clinical Impact
The shift is already producing tangible outcomes.
A recent example is a collaboration between Merck and Suzhou Zelgen Biopharmaceuticals, which introduced recombinant human thyrotropin for injection into the Chinese market.
The treatment addresses a long-standing clinical challenge in the management of differentiated thyroid cancer.
Traditionally, patients undergoing post-operative monitoring must suspend thyroid hormone therapy to elevate hormone levels for testing—often causing discomfort and, in some cases, medical risks, particularly for elderly patients or those with cardiovascular conditions.
The new therapy allows patients to remain on hormone treatment, reducing both discomfort and clinical risk while enabling more precise follow-up care.
Beyond its immediate medical benefits, the product illustrates a broader trend: Chinese-developed innovations are increasingly being translated into real-world clinical solutions through global collaboration.
A Two-Way Flow of Innovation
The growing number of licensing deals highlights another important development—the emergence of a two-way flow of innovation.
In the past, multinational companies primarily introduced foreign-developed drugs into China. Today, Chinese firms are increasingly licensing their innovations outward, leveraging global partners to reach international markets.
This model allows:
-
Chinese biotech companies to scale globally
-
Multinationals to access a rapidly expanding innovation pipeline
The result is a more interconnected global pharmaceutical ecosystem, with China playing a far more central role than before.
A Long-Term Strategic Bet
For companies like Merck, deepening engagement in China is not viewed as a short-term opportunity, but as a long-term strategic investment.
The country’s combination of:
-
Strong scientific talent
-
Expanding clinical capabilities
-
Supportive regulatory evolution
-
Large and increasingly sophisticated patient base
makes it an increasingly attractive environment for pharmaceutical innovation.
At the same time, China’s ambition to bring its medical breakthroughs to the global stage is creating new opportunities for collaboration.
Redefining China’s Role in Global Healthcare
Taken together, these developments point to a broader redefinition of China’s role in the global pharmaceutical industry.
China is no longer simply a high-growth market for foreign drugmakers.
It is becoming:
-
A source of innovation
-
A partner in development
-
And a driver of global healthcare transformation
For multinational companies, the strategic question is shifting accordingly.
It is no longer just how to enter China—
but how to integrate China into global innovation and commercialization strategies.
Conclusion
As partnerships deepen and innovation flows in both directions, China’s pharmaceutical sector is entering a new phase—one defined not by scale alone, but by its growing influence on the future of global medicine.
For the world’s leading drugmakers, staying relevant in that future increasingly means working not just in China, but with China.